A study led by Dr. Peter Canoll's lab, in collaboration with researchers at Columbia University Irving Medical Center, Zuckerman Institute, and Irving Institute for Cancer Dynamics, along with ...

A new study published in the recent issue of journal of Urology revealed the effect of radiation timing on outcomes for ...

Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the fourth quarter of 2024. Core earnings ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

In an era defined by mounting mental health challenges, few leaders are as effective in bridging the gap between science and ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid ...

Live Updates Make sure to refresh this page periodically for updates. Deep Dive into ABBV's Earnings Call 11:53 am Looking ...

There were 64 passengers aboard the plane, and three Army soldiers in the helicopter, according to officials. Here's a look ...

It’s woolly hat weather in Oxford and though the porter in the lodge at New College is friendly, it’s a relief to see Professor Masud Husain quickly appear to take me to a warm room for our interview.

The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency ...